Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
18 sept. 2024 07h00 HE
|
OXB
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford, UK – 18 September 2024: OXB (LSE:OXB), a quality and innovation-led cell and gene...
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
02 sept. 2024 07h00 HE
|
Oxford BioMedica plc
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OXB" or “the Company”), a quality and...
Oxford Biomedica to host a free webinar showcasing its AAV expertise
27 août 2024 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica to host a free webinar showcasing its AAV expertise Oxford, UK - 27 August 2024: On Wednesday 11 September 2024, Oxford Biomedica, a quality and innovation-led cell and gene therapy...
Oxford Biomedica – Half Year Trading Update and Notice of Interim Results
08 août 2024 07h00 HE
|
Oxford BioMedica plc
Half Year Trading Update and Notice of Interim Results Full year 2024 revenue and medium-term financial guidance reiterated; underpinned by OXB’s growing market share in the expanding cell and gene...
Oxford Biomedica announces CFO transition
17 juil. 2024 07h06 HE
|
Oxford BioMedica plc
Oxford Biomedica announces Chief Financial Officer transition - Lucinda Crabtree to join as Chief Financial Officer - Oxford, UK – 17 July 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”,...
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
05 mars 2024 07h00 HE
|
Oxford BioMedica plc
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30%Projected FY2024...
Oxford Biomedica completes acquisition of ABL Europe
29 janv. 2024 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple...
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing
23 janv. 2024 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and...
Business Update
07 déc. 2023 07h00 HE
|
Oxford BioMedica plc
Business Update Current contracted value signed in 2023 of £124 million, an increase of 47% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing)On...
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO
04 déc. 2023 07h04 HE
|
Oxford BioMedica plc
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO Oxford Biomedica announces the signing of a sale and purchase agreement...